Non genital warts infection
Conditions
Brief summary
Disappearance of warts at the end of treatment (6-month visit)
Detailed description
- Disappearance of warts at 4 months. - Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 4 months and 6 months, - Warts recurrence at 3-month visit post-treatment - Pain evaluation during the study by VAS and consumption of antalgic medication. - Safety: occurrence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug.
Interventions
DRUG2LVERU JUNIOR granules en gélules à ouvrir
DRUGPlacebo
DRUG2LVERU granules en gélules à ouvrir
Sponsors
Labo'Life Belgium
Eligibility
Sex/Gender
All
Age
0 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disappearance of warts at the end of treatment (6-month visit) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Disappearance of warts at 4 months. - Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 4 months and 6 months, - Warts recurrence at 3-month visit post-treatment - Pain evaluation during the study by VAS and consumption of antalgic medication. - Safety: occurrence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug. | — |
Countries
Belgium
Outcome results
None listed